Another paradox in Crohn's disease: New onset of psoriasis in a patient receiving tumor necrosis factor-α antagonist [4]

Inflammatory Bowel Diseases

Volumn 13, Issue 8, 2007, Pages 1059-1061

  Angelucci, Erika ^a   Cocco, Andrea ^a   Viscido, Angelo ^a   Vernia, Piero ^a   Caprilli, Renzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MESALAZINE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; HISTOPATHOLOGY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; SKIN DEFECT;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; MALE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548146307     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20137     Document Type: Letter

References (5)

1. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol. 2006;54(Suppl 2):S67-80.
2. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374.
3. Ritchlin C, Tausk F. A medical conundrum. Onset of psoriasis in patients receiving tumour necrisis factor agents. Ann Rheum Dis. 2006;65:1541-1544.
4. Thurber M, Feasel A, Stroehlein J, et al. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004;3:439-440.
5. Verea MM, Del Pozo J, Yebra-Pimentel MT, et al. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004;38:54-57.